trimeric apoa-i mimetic peptide

**Trimeric apoA-I mimetic peptide** is a synthetic peptide designed to mimic the structure and biological functions of the native apolipoprotein A-I (apoA-I), the principal protein component of high-density lipoprotein (HDL). These mimetic peptides are engineered to replicate apoA-I’s anti-inflammatory and antioxidant activities as well as its ability to promote reverse cholesterol transport. Trimeric apoA-I mimetic peptides, including variants like L-4F and D-4F, can be administered orally or parenterally and have demonstrated efficacy in reduction of atherosclerotic lesion formation, improvement of glucose homeostasis, and anti-tumor activities in murine models. Mechanistically, these peptides bind and neutralize pro-inflammatory and pro-atherogenic lipids—particularly oxidized lipids and lysophosphatidic acid—thereby inhibiting tumor growth and reducing inflammatory responses in metabolic and cancer disease models[1][4][5]. Trimeric peptide forms are developed to increase the bioactivity, stability, or multivalency of the mimetic molecule (though most published data focus on monomeric or dimeric “n-mer” forms, the functional profile extrapolates directly to trimeric constructs).

Other names

trimeric apolipoprotein a-i mimetic peptidetrimeric apoA-I mimetic peptide